Familial hypercholesterolaemia is a relatively frequently occurring disease that is strongly associated with vascular disease. Current treatment with cholesterol-lowering agents is partly effective but shows variable responses between patients with familial hypercholesterolaemia. Recently, new cholesterol-lowering drugs have been developed. Here we describe the most promising of these new agents for which results from phase 2 or phase 3 trials are available. We will discuss the data regarding lipid-lowering potential and safety issues and speculate about the potential reductions of the residual risk of statin-treated FH patients.

Apolipoprotein B, CETP, Familial hypercholesterolemia, MTP, PCSk9, Synthesis inhibitor, Treatment
hdl.handle.net/1765/85091
The Netherlands Journal of Medicine
Department of General Practice

Ezzahti, M, Sijbrands, E.J.G, Mulder, M.T, & Roeters van Lennep, J.E. (2013). Familial hypercholesterolaemia: New treatment options. The Netherlands Journal of Medicine (Vol. 71, pp. 227–233). Retrieved from http://hdl.handle.net/1765/85091